Study on Personalized Care to Improve Function and Cognitive Health in Young People with Early Psychosis

What this Trial Is About

Researchers are studying early psychosis, including schizophrenia, focusing on young people aged 15 to 30 who are at ultra-high risk or have had a first episode of psychosis. The study explores how cognitive deficits and biological factors like inflammation and oxidative stress contribute to the disorder, aiming to improve functional recovery by using a combined personalized care approach. This approach includes cognitive training and neuroprotective strategies tailored to each persons needs and biological profile. The study compares several treatment groups, including standard treatment as usual TAU featuring psycho-education and cognitive behavioral therapy, TAU combined with cognitive training via digital applications and virtual reality for those with higher deficits, TAU combined with personalized neuroprotective supplements such as Vitamin B12, folinic acid, Omega 3, and N-acetyl-cysteine, and TAU combined with both cognitive training and neuroprotective strategies. Supplements and cognitive training are provided over 12 weeks, with digital and virtual reality tools designed to be accessible and engaging. Participants will be assessed multiple times at baseline, then at 3 to 4 months and again at 6 to 8 months after starting interventions. Evaluations include global functioning, cognitive abilities, motivation, quality of life, medication adherence, and biological markers. Researchers will also monitor the acceptability and satisfaction with the e-health application used for cognitive training. The studys primary outcome is improvement in global functioning measured 3 to 4 months after starting treatment, with ongoing follow-up for up to four years to assess longer-term effects and cost-effectiveness.

Efficiency of a Composite Personalised Care on Functional Outcome in Early Psychosis